More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at...

|About: Alexza Pharmaceuticals, Inc. (ALXA)|By:, SA News Editor

More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash.